Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Fink

Showing results (791-800 of 853) with videos related to

Pageof 86
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II TrialDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2022
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial TumorsAndrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, et al.
The Journal of Clinical Investigation|December 15, 2020
Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidatesJim Boonyaratanakornkit, Chihiro Morishima, Stacy Selke, et al.
Critical Care (London, England)|April 20, 2021
Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort studyPavan K Bhatraju, Eric D Morrell, Leila Zelnick, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Blood|November 17, 2020
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entityM K Gandhi, T Hoang, S C Law, et al.
Annals of Family Medicine|March 24, 2026
Effect of an Advanced Community Paramedic Program to Shorten or Prevent Hospitalizations: A Pragmatic, Point-of-Care, Randomized Clinical TrialRozalina G McCoy, Michael B Juntunen, Jennifer L Ridgeway, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2017
X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stabilityBeatriz E Marciano, Christa S Zerbe, E Liana Falcone, et al.
Frontiers in Pediatrics|February 14, 2022
Global PARITY: Study Design for a Multi-Centered, International Point Prevalence Study to Estimate the Burden of Pediatric Acute Critical Illness in Resource-Limited SettingsQalab Abbas, Adrian Holloway, Paula Caporal, et al.
Cell Reports. Medicine|July 9, 2024
Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19Shreya M Kanth, Julio A Huapaya, Salina Gairhe, et al.
Pageof 86

Showing results (791-800 of 853) with videos related to

Sort By:
Pageof 86
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II TrialDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2022
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial TumorsAndrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, et al.
The Journal of Clinical Investigation|December 15, 2020
Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidatesJim Boonyaratanakornkit, Chihiro Morishima, Stacy Selke, et al.
Critical Care (London, England)|April 20, 2021
Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort studyPavan K Bhatraju, Eric D Morrell, Leila Zelnick, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Blood|November 17, 2020
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entityM K Gandhi, T Hoang, S C Law, et al.
Annals of Family Medicine|March 24, 2026
Effect of an Advanced Community Paramedic Program to Shorten or Prevent Hospitalizations: A Pragmatic, Point-of-Care, Randomized Clinical TrialRozalina G McCoy, Michael B Juntunen, Jennifer L Ridgeway, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2017
X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stabilityBeatriz E Marciano, Christa S Zerbe, E Liana Falcone, et al.
Frontiers in Pediatrics|February 14, 2022
Global PARITY: Study Design for a Multi-Centered, International Point Prevalence Study to Estimate the Burden of Pediatric Acute Critical Illness in Resource-Limited SettingsQalab Abbas, Adrian Holloway, Paula Caporal, et al.
Cell Reports. Medicine|July 9, 2024
Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19Shreya M Kanth, Julio A Huapaya, Salina Gairhe, et al.
Pageof 86